Cargando…

Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy

Primary liver tumors are a heterogeneous group of malignancies. Besides classical hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), combined and intermediate forms of liver cancer exist and can express stem-cell markers like nuclear cell adhesion molecule (NCAM-1/CD56), c-kit (CD117) or ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler, Bruno Christian, Waldburger, Nina, Schlamp, Kai, Jäger, Dirk, Weiss, Karl Heinz, Schulze-Bergkamen, Henning, Schirmacher, Peter, Springfeld, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601796/
https://www.ncbi.nlm.nih.gov/pubmed/28938700
http://dx.doi.org/10.18632/oncotarget.19000
_version_ 1783264459086626816
author Köhler, Bruno Christian
Waldburger, Nina
Schlamp, Kai
Jäger, Dirk
Weiss, Karl Heinz
Schulze-Bergkamen, Henning
Schirmacher, Peter
Springfeld, Christoph
author_facet Köhler, Bruno Christian
Waldburger, Nina
Schlamp, Kai
Jäger, Dirk
Weiss, Karl Heinz
Schulze-Bergkamen, Henning
Schirmacher, Peter
Springfeld, Christoph
author_sort Köhler, Bruno Christian
collection PubMed
description Primary liver tumors are a heterogeneous group of malignancies. Besides classical hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), combined and intermediate forms of liver cancer exist and can express stem-cell markers like nuclear cell adhesion molecule (NCAM-1/CD56), c-kit (CD117) or epithelial cell adhesion molecule (EpCAM) together with high proliferative activity. Liver tumors with progenitor-cell features are associated with an unfavorable prognosis, but the phenotype has not resulted in therapeutic consequences so far. We report three patients with liver cancers with stem/progenitor-cell features that responded exceptionally well to chemotherapy. These encouraging results indicate that the identification of liver cancer with stem/progenitor-cell phenotype in a patient´s tumor might justify an attempt to treat the patient with chemotherapy. Further case studies and finally clinical trials will be necessary to determine the optimal treatment for patients with this rare form of liver cancer.
format Online
Article
Text
id pubmed-5601796
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56017962017-09-21 Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy Köhler, Bruno Christian Waldburger, Nina Schlamp, Kai Jäger, Dirk Weiss, Karl Heinz Schulze-Bergkamen, Henning Schirmacher, Peter Springfeld, Christoph Oncotarget Case Report Primary liver tumors are a heterogeneous group of malignancies. Besides classical hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), combined and intermediate forms of liver cancer exist and can express stem-cell markers like nuclear cell adhesion molecule (NCAM-1/CD56), c-kit (CD117) or epithelial cell adhesion molecule (EpCAM) together with high proliferative activity. Liver tumors with progenitor-cell features are associated with an unfavorable prognosis, but the phenotype has not resulted in therapeutic consequences so far. We report three patients with liver cancers with stem/progenitor-cell features that responded exceptionally well to chemotherapy. These encouraging results indicate that the identification of liver cancer with stem/progenitor-cell phenotype in a patient´s tumor might justify an attempt to treat the patient with chemotherapy. Further case studies and finally clinical trials will be necessary to determine the optimal treatment for patients with this rare form of liver cancer. Impact Journals LLC 2017-06-05 /pmc/articles/PMC5601796/ /pubmed/28938700 http://dx.doi.org/10.18632/oncotarget.19000 Text en Copyright: © 2017 Köhler et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Köhler, Bruno Christian
Waldburger, Nina
Schlamp, Kai
Jäger, Dirk
Weiss, Karl Heinz
Schulze-Bergkamen, Henning
Schirmacher, Peter
Springfeld, Christoph
Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title_full Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title_fullStr Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title_full_unstemmed Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title_short Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
title_sort liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601796/
https://www.ncbi.nlm.nih.gov/pubmed/28938700
http://dx.doi.org/10.18632/oncotarget.19000
work_keys_str_mv AT kohlerbrunochristian livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT waldburgernina livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT schlampkai livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT jagerdirk livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT weisskarlheinz livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT schulzebergkamenhenning livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT schirmacherpeter livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy
AT springfeldchristoph livercancerswithstemprogenitorcellfeaturesararechemotherapysensitivemalignancy